Dose estimation for children

10.1046/j.1472-8206.2003.00123.x

1999, Medicines for children.

10.1136/fn.80.2.F142

10.1136/adc.85.3.177

10.1136/bmj.320.7227.79

10.1016/S0140-6736(96)91182-4

10.1046/j.1365-2125.2000.00125.x

Serlin MJ, 1980, Propanolol in the control of blood pressure: a dose–response study, Br J Clin Pharmacol, 27, 586

British Paediatric Association/Association of British Pharmaceutical Industries., 1996, Licensing medicines for children.

10.1093/bja/78.5.601

10.1111/j.1651-2227.1999.tb00191.x

10.1136/adc.87.6.462

10.1542/peds.110.5.e53

10.1046/j.1365-2125.2002.t01-3-01689.x

Ekin‐DaukesS McLayJS TaylorMWet al.Antibiotic prescribing for children. Too much and too little? Retrospective observational study in primary case.Br J. Clin Pharmacol2003;56:92–95.

10.1056/NEJM196004212621601

10.1046/j.1365-2125.2002.01652.x

10.1136/adc.87.6.457

Gilman JT, 1986, Inadequacy of FDA dosing guidelines for theophylline use in neonates, Drug Intell Clin Pharm, 20, 481

10.1212/WNL.29.11.1445

10.1136/adc.84.4.337

10.1056/NEJMhpr021646

European Agency for the Evaluation of Medicinal Products/Committee for European Commission. Commission Services Reflection Paper Considerations for a Commission proposal on medicinal products for paediatric use.http://www.pharmacos.eudra.org/F2/home.html

Baber N, 2003, Textbook of pharmaceutical medicine, 247

Guidance For Industry: General Considerations for Pediatric Pharmcokinetic Studies.

10.1093/bja/89.3.428

10.1046/j.1460-9592.2002.00616.x

Tooley A, 1999, Acute inhibition of methadone metabolism by ritonavir: projection of interindividual variability from in vitro data, Br J Clin Pharmacol, 48, 883P

Yang JS, 2001, Prediction of fluconazole interaction with midazolam and trazolam: incorporatying population variability, Br J Clin Pharmacol, 52, 484P

Yang JS, 2001, Prediction of ketoconazole interaction with midazolam, alparzolam and triazolam: incorpoating population variability, Br J Clin Pharmacol, 52, 472P